logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Bioivt Acquires Cypex, A Leading Manufacturer Of Drug-Metabolizing Enzymes

Aug 08, 2022•over 3 years ago

Acquiring Company

BioIVT

Acquired Company

Cypex

Description

BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it has acquired Cypex, a renowned manufacturer of recombinant xenobiotic metabolizing enzymes, based in Dundee, Scotland. Cypex's extensive enzyme portfolio covers a wide range of proteins involved in drug metabolism.

Company Information

Company

BioIVT

About

BioIVT is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. And as the premier supplier of hepatic products, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit www.bioivt.com or follow the company on Twitter @BioIVT.

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed